Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Solid Tumors
Interventions: M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen; Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumors With and Without Brain Metastases
Interventions: ANG1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Canton, Ohio • Houston, Texas • San Antonio, Texas

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Vemurafenib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more

Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions: STAR0602, Sacituzumab Govitecan (SG); Drug
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Advanced Cancer, Metastatic Solid Tumor, Solid Tumor
Interventions: TACH101; Drug
Lead sponsor: Tachyon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Orange, California • Denver, Colorado • Orlando, Florida + 5 more

Conditions: Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ALVAC-CEA vaccine, aldesleukin, sargramostim, vaccinia-CEA vaccine; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Interventions: CF33-hNIS, Pembrolizumab, Modified FOLFOX; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more

Conditions: Neoplasms, Lung
Interventions: Risvutatug rezetecan, Ivonescimab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Wilson, North Carolina • Canton, Ohio

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions: Oral repotrectinib (TPX-0005); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 49
States / cities: Duarte, California • Glendale, California • La Jolla, California + 36 more

Conditions: Advanced Solid Tumors, Lymphoid Malignancies
Interventions: Bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Conditions: Advanced Solid Tumours
Interventions: AZD2811; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: MK-1484, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Sioux Falls, South Dakota • San Antonio, Texas

Conditions: Solid Tumor Cancer, Lymphoma
Interventions: SB-485232; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Advanced Malignant Solid Neoplasm
Interventions: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration; Biological · Drug
Lead sponsor: Tianhong Li; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Advanced Pancreatic Cancer, Solid Tumor Malignancies
Interventions: ProAgio Dose Levels (DL) 1,2,3, ProAgio Dose Levels (DL) 4,5,6, ProAgio Dose Levels 4a,5a,6a; Drug
Lead sponsor: ProDa BioTech, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor
Interventions: MSC2015103B; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Solid Tumor
Interventions: Cetuximab, Cisplatin, 5 - Fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more

Conditions: Solid Tumors
Interventions: Ramucirumab (IMC-1121B), Irinotecan, Folinic acid, 5-Fluorouracil; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio + 2 more

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions: ATX-559; Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: topotecan hydrochloride, bortezomib, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, carboplatin, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lymphoid Malignancies, Solid Tumors
Interventions: RTA 402; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
Interventions: A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, B3: AMG 386 15mg/kg + Topotecan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more

Search by objective public record fields.

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

MSC2015103B in Solid Tumors

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Study in Advanced Solid Tumors

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR